offline
Merck Smashes Q1 Earnings Estimate, Boosts 2019 Outlook, as Keytruda Sales Surge
Merck posted stronger-than-expected first quarter earnings Tuesday, and lifted its 2019 profit guidance, as its blockbuster lung cancer treatment topped $2.2 billion.
...
Merck said GAAP earnings for the three months ending in March came in at $1.12 per share, more than four times higher than the same period last year and seven cents ahead of the Street consensus forecast. Group revenues, Merck said, rose 8% to $10.8 billion thanks in part to a 55% surge in sales of Keytruda lung cancer treatment.
...
https://www.thestreet.com/investing/earn...yptr=yahoo
![[Bild: MRKc1dl1428.png]](https://finviz.com/publish/043019/MRKc1dl1428.png)
Merck posted stronger-than-expected first quarter earnings Tuesday, and lifted its 2019 profit guidance, as its blockbuster lung cancer treatment topped $2.2 billion.
...
Merck said GAAP earnings for the three months ending in March came in at $1.12 per share, more than four times higher than the same period last year and seven cents ahead of the Street consensus forecast. Group revenues, Merck said, rose 8% to $10.8 billion thanks in part to a 55% surge in sales of Keytruda lung cancer treatment.
...
https://www.thestreet.com/investing/earn...yptr=yahoo
__________________
